306 related articles for article (PubMed ID: 10867446)
1. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials.
Farlow MR; Cyrus PA
Dement Geriatr Cogn Disord; 2000; 11(4):202-11. PubMed ID: 10867446
[TBL] [Abstract][Full Text] [Related]
2. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
[TBL] [Abstract][Full Text] [Related]
4. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
5. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study.
Dubois B; McKeith I; Orgogozo JM; Collins O; Meulien D
Int J Geriatr Psychiatry; 1999 Nov; 14(11):973-82. PubMed ID: 10556869
[TBL] [Abstract][Full Text] [Related]
6. Metrifonate for Alzheimer's disease.
López-Arrieta JM; Schneider L
Cochrane Database Syst Rev; 2006 Apr; (2):CD003155. PubMed ID: 16625573
[TBL] [Abstract][Full Text] [Related]
7. Metrifonate treatment of AD: influence of APOE genotype.
Farlow MR; Cyrus PA; Nadel A; Lahiri DK; Brashear A; Gulanski B
Neurology; 1999 Dec; 53(9):2010-6. PubMed ID: 10599773
[TBL] [Abstract][Full Text] [Related]
8. Metrifonate enhances the ability of Alzheimer's disease patients to initiate, organize, and execute instrumental and basic activities of daily living.
Gélinas I; Gauthier S; Cyrus PA
J Geriatr Psychiatry Neurol; 2000; 13(1):9-16. PubMed ID: 10753002
[TBL] [Abstract][Full Text] [Related]
9. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group.
Cummings JL; Cyrus PA; Bieber F; Mas J; Orazem J; Gulanski B
Neurology; 1998 May; 50(5):1214-21. PubMed ID: 9595966
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease.
Cummings JL; Nadel A; Masterman D; Cyrus PA
J Geriatr Psychiatry Neurol; 2001; 14(2):101-8. PubMed ID: 11419566
[TBL] [Abstract][Full Text] [Related]
11. The clinical trial protocol of the Metrifonate in Alzheimer's Trial (MALT).
McKeith IG
Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():2-7. PubMed ID: 9718228
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.
Xiao S; Wang T; Ma X; Qin Y; Li X; Zhao Z; Liu X; Wang X; Xie H; Jiang Q; Sun L; Luo B; Shang L; Chen W; Bai Y; Tang M; He M; Wu L; Ma Q; Hou D; He J
Age Ageing; 2017 Sep; 46(5):767-773. PubMed ID: 28419192
[TBL] [Abstract][Full Text] [Related]
13. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease.
Becker RE; Colliver JA; Markwell SJ; Moriearty PL; Unni LK; Vicari S
Alzheimer Dis Assoc Disord; 1996; 10(3):124-31. PubMed ID: 8876775
[TBL] [Abstract][Full Text] [Related]
14. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
[TBL] [Abstract][Full Text] [Related]
15. The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: results from the MALT clinical trial. Metrifonate in Alzheimer's Disease Trial.
Shikiar R; Shakespeare A; Sagnier PP; Wilkinson D; McKeith I; Dartigues JF; Dubois B
J Am Geriatr Soc; 2000 Mar; 48(3):268-74. PubMed ID: 10733052
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
[TBL] [Abstract][Full Text] [Related]
17. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
De Jesus Moreno Moreno M
Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
[TBL] [Abstract][Full Text] [Related]
18. Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.
Aronson S; Van Baelen B; Kavanagh S; Schwalen S
Drugs Aging; 2009; 26(3):231-9. PubMed ID: 19358618
[TBL] [Abstract][Full Text] [Related]
19. Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease.
Mega MS; Cummings JL; O'Connor SM; Dinov ID; Reback E; Felix J; Masterman DL; Phelps ME; Small GW; Toga AW
Neuropsychiatry Neuropsychol Behav Neurol; 2001 Jan; 14(1):63-8. PubMed ID: 11234910
[TBL] [Abstract][Full Text] [Related]
20. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
